| Dr Rama Atla, MD | |
|
226 S Anderson St, Suite A, Elwood, IN 46036-2015 | |
| (765) 552-3000 | |
| Not Available |
| Full Name | Dr Rama Atla |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 24 Years |
| Location | 226 S Anderson St, Elwood, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598928863 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 01069923A (Indiana) | Primary |
| 207Q00000X | Family Medicine | Q4560 (Texas) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Christus Mother Frances Hospital | Tyler, TX | Hospital |
| Dallas Regional Medical Center | Mesquite, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Star Md Pllc | 2860773389 | 14 |
| Christus Trinity Clinic | 3072426741 | 1227 |
News Archive
Researchers at Hospital for Special Surgery have launched a study to determine if a treatment using stem cells could help people with painful knee arthritis.
Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.
A "combined therapy" approach to treating the most common form of brain cancer could prove promising, scientists say.
"Cytomegalovirus, beware of this new research group!" This could be the motto of a new research unit recently approved by the German Research Foundation. It is titled: "Advanced concepts in cellular control of cytomegalovirus ".
› Verified 3 days ago
| Entity Name | Christus Trinity Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285684225 PECOS PAC ID: 3072426741 Enrollment ID: O20031204001091 |
News Archive
Researchers at Hospital for Special Surgery have launched a study to determine if a treatment using stem cells could help people with painful knee arthritis.
Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.
A "combined therapy" approach to treating the most common form of brain cancer could prove promising, scientists say.
"Cytomegalovirus, beware of this new research group!" This could be the motto of a new research unit recently approved by the German Research Foundation. It is titled: "Advanced concepts in cellular control of cytomegalovirus ".
› Verified 3 days ago
| Entity Name | Texas Health Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174573596 PECOS PAC ID: 4385535954 Enrollment ID: O20040323000759 |
News Archive
Researchers at Hospital for Special Surgery have launched a study to determine if a treatment using stem cells could help people with painful knee arthritis.
Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.
A "combined therapy" approach to treating the most common form of brain cancer could prove promising, scientists say.
"Cytomegalovirus, beware of this new research group!" This could be the motto of a new research unit recently approved by the German Research Foundation. It is titled: "Advanced concepts in cellular control of cytomegalovirus ".
› Verified 3 days ago
| Entity Name | Concord Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083630610 PECOS PAC ID: 0446296818 Enrollment ID: O20050707000531 |
News Archive
Researchers at Hospital for Special Surgery have launched a study to determine if a treatment using stem cells could help people with painful knee arthritis.
Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.
A "combined therapy" approach to treating the most common form of brain cancer could prove promising, scientists say.
"Cytomegalovirus, beware of this new research group!" This could be the motto of a new research unit recently approved by the German Research Foundation. It is titled: "Advanced concepts in cellular control of cytomegalovirus ".
› Verified 3 days ago
| Entity Name | Sound Inpatient Physicians Of Texas I, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831424563 PECOS PAC ID: 8729133640 Enrollment ID: O20090828000300 |
News Archive
Researchers at Hospital for Special Surgery have launched a study to determine if a treatment using stem cells could help people with painful knee arthritis.
Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.
A "combined therapy" approach to treating the most common form of brain cancer could prove promising, scientists say.
"Cytomegalovirus, beware of this new research group!" This could be the motto of a new research unit recently approved by the German Research Foundation. It is titled: "Advanced concepts in cellular control of cytomegalovirus ".
› Verified 3 days ago
| Entity Name | Hospitalist Medicine Physicians Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629307095 PECOS PAC ID: 3476688318 Enrollment ID: O20100317001021 |
News Archive
Researchers at Hospital for Special Surgery have launched a study to determine if a treatment using stem cells could help people with painful knee arthritis.
Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.
A "combined therapy" approach to treating the most common form of brain cancer could prove promising, scientists say.
"Cytomegalovirus, beware of this new research group!" This could be the motto of a new research unit recently approved by the German Research Foundation. It is titled: "Advanced concepts in cellular control of cytomegalovirus ".
› Verified 3 days ago
| Entity Name | Concord Medical Group Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750790762 PECOS PAC ID: 7810117223 Enrollment ID: O20141007002567 |
News Archive
Researchers at Hospital for Special Surgery have launched a study to determine if a treatment using stem cells could help people with painful knee arthritis.
Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.
A "combined therapy" approach to treating the most common form of brain cancer could prove promising, scientists say.
"Cytomegalovirus, beware of this new research group!" This could be the motto of a new research unit recently approved by the German Research Foundation. It is titled: "Advanced concepts in cellular control of cytomegalovirus ".
› Verified 3 days ago
| Entity Name | Star Md Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972059392 PECOS PAC ID: 2860773389 Enrollment ID: O20161221001053 |
News Archive
Researchers at Hospital for Special Surgery have launched a study to determine if a treatment using stem cells could help people with painful knee arthritis.
Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.
A "combined therapy" approach to treating the most common form of brain cancer could prove promising, scientists say.
"Cytomegalovirus, beware of this new research group!" This could be the motto of a new research unit recently approved by the German Research Foundation. It is titled: "Advanced concepts in cellular control of cytomegalovirus ".
› Verified 3 days ago
| Entity Name | Hospitalist Medicine Physicians Of Texas - Tyler, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861037590 PECOS PAC ID: 4880021211 Enrollment ID: O20200225001897 |
News Archive
Researchers at Hospital for Special Surgery have launched a study to determine if a treatment using stem cells could help people with painful knee arthritis.
Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.
A "combined therapy" approach to treating the most common form of brain cancer could prove promising, scientists say.
"Cytomegalovirus, beware of this new research group!" This could be the motto of a new research unit recently approved by the German Research Foundation. It is titled: "Advanced concepts in cellular control of cytomegalovirus ".
› Verified 3 days ago
| Entity Name | Round Table Specialist Group, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497152268 PECOS PAC ID: 1254754609 Enrollment ID: O20200702000716 |
News Archive
Researchers at Hospital for Special Surgery have launched a study to determine if a treatment using stem cells could help people with painful knee arthritis.
Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.
A "combined therapy" approach to treating the most common form of brain cancer could prove promising, scientists say.
"Cytomegalovirus, beware of this new research group!" This could be the motto of a new research unit recently approved by the German Research Foundation. It is titled: "Advanced concepts in cellular control of cytomegalovirus ".
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rama Atla, MD 10330 N Meridian St, Suite 201, Indianapolis, IN 46290-1024 Ph: () - | Dr Rama Atla, MD 226 S Anderson St, Suite A, Elwood, IN 46036-2015 Ph: (765) 552-3000 |
News Archive
Researchers at Hospital for Special Surgery have launched a study to determine if a treatment using stem cells could help people with painful knee arthritis.
Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.
A "combined therapy" approach to treating the most common form of brain cancer could prove promising, scientists say.
"Cytomegalovirus, beware of this new research group!" This could be the motto of a new research unit recently approved by the German Research Foundation. It is titled: "Advanced concepts in cellular control of cytomegalovirus ".
› Verified 3 days ago
Mr. Ryan D. Torrie, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1331 S A St, Elwood, IN 46036 Phone: 765-552-4600 Fax: 765-552-4680 | |
Robert James Helm, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1520 S R St, Elwood, IN 46036 Phone: 765-552-7316 Fax: 765-552-7306 | |
Onyekachi U Nwabuko, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1331 S A St, Elwood, IN 46036 Phone: 765-552-4743 | |
Steven Gatewood, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1515 S 19th St, Elwood, IN 46036 Phone: 765-298-2800 Fax: 765-298-2820 | |
Robert Manford Irick, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1500 S B St, Elwood, IN 46036 Phone: 765-552-1000 | |
Ronald Duncan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1515 S 19th St, Elwood, IN 46036 Phone: 765-298-2800 Fax: 765-298-2820 |